As a result, strategies ranging from the design and preparation of potent synthetic small-molecule antagonists (i.e., glycomimetics) to the acquisition of large biologics from natural sources are being employed to target Gal3 for therapeutic intervention against viral diseases, as well as other inflammatory diseases. Here, LGALS3 is linked to viral infectious disease.